Drug intelligence / Profile preview

RO5024118

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Inhalation

Overview

RO5024118 (also known as R7103) is a selective vasoactive intestinal peptide receptor 2 (VPAC2) agonist developed by Roche for the treatment of chronic obstructive pulmonary disease (COPD). It is a small molecule designed to provide dual bronchodilatory and anti-inflammatory activity by targeting VPAC2 receptors expressed in the respiratory tract. The compound was derived through chemical modification of an earlier VPAC2 agonist, RO0251553. RO5024118 has been evaluated in Phase 1 multiple-ascending dose clinical trials to investigate its safety, tolerability, pharmacokinetics, and pharmacodynamics following repeated inhaled administration in patients with moderate-to-severe COPD.

Targets

VIPR2 (Vasoactive intestinal polypeptide receptor 2)

Beyond the preview

Go deeper on RO5024118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5024118.

Explore the full profile